The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Thank you, Vimal.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 12, 2022 / 3:00PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Healthcare Conference
Maybe let's start with the launch of IGALMI, recently approved and you're in the preparation for the launch process. Maybe you could give us a
status update and where you're at now and what remains to be done?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. So maybe we could talk a little bit about the initial strategy for bringing IGALMI into different patient settings. Where do you see it being
administered primarily now and then in the future as you expand on that?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. What needs to happen to remove that language from the label? And how does use in that unsupervised setting differ as far as achieving
market penetration and frequency of use and those sort of aspects?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 12, 2022 / 3:00PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Got it. So you did announce the price earlier this week, $105 a dose. Can you comment on the strategy? And what factors led you to choose that
price?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Now when it comes to the competition and other options for these patients, a lot of those are generic and going to be at a much lower price.
So how do you position your argument for use of IGALMI relative to those options? And what are you doing to demonstrate the value to the overall
system from using something that may be more expensive upfront but could save cost down the road?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great.
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. That's really helpful. So you mentioned this is kind of a unique launch. There aren't a lot of good analogues. So what are some of the metrics
we should expect to help us understand the progress of the launch as it progresses?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 12, 2022 / 3:00PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. And then what is the strategy for commercializing IGALMI outside of the U.S.?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Maybe we can switch gears and talk about some of the other indications that you're pursuing for 501. You recently initiated dosing in the
TRANQUILITY trial in Alzheimer's. What are your expectations from this indication and the opportunity there for IGALMI?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. And then you're also pursuing major depressive disorder. What would a trial there look like for 501?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. And how should we think about that market opportunity within MDD? And do you have any sense of what percentage of current patients
need something beyond what they're getting from standard of care?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Let's talk a little bit about 701 and OnkosXcel. Maybe we could start with your thoughts on the advantage of creating OnkosXcel to focus
on your oncology treatments.
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. And then you've shown some impressive data so far with 701 in some difficult tumor types. What is the path from here to -- towards an
eventual approval?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: And then where else can you go within oncology beyond these initial tumor types, either with 701 as that concept is approved, or even beyond if
we should expect additional programs to come from the AI engine?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 12, 2022 / 3:00PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Well, with our remaining time, let's maybe just turn to the AI platform overall. You've been pretty impressive in showing the speed of
development with IGALMI coming out of the platform. Where should we expect future programs to focus coming out of the AI platform?
| 
